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Ageing and cancer as diseases of epigenesis
SCOTT F GILBERT
Martin Laboratories of Biology, Swarthmore College, Swarthmore, PA 19081, USA
(Email, sgilber1@swarthmore.edu)
Cancer and ageing are often said to be diseases of development. During the past ﬁfty years, the genetic components of
cancer and ageing have been intensely investigated since development, itself, was seen to be an epiphenomenon of the
genome. However, as we have learned more about the expression of the genome, we ﬁnd that differences in expression
can be as important as differences in alleles. It is easier to inactivate a gene by methylation than by mutation, and given
that appropriate methylation is essential for normal development, one can immediately see that diseases would result
as a consequence of inappropriate epigenetic methylation. While ﬁrst proposed by Boris Vanyushin in 1973, recent
studies have conﬁrmed that inappropriate methylation not only causes diseases, and it also may be the critical factor
in ageing and cancers.
[Gilbert S F 2009 Ageing and cancer as diseases of epigenesist; J. Biosci. 34 601–604]

1. Ageing as an epigenetic disease
There is now substantial evidence that many components of
the normal ageing syndrome are due to the accumulation of
errors in DNA methylation (see Fraga and Esteller 2007).
Some of the ﬁrst evidence for the roles of epigenetic
methylation in ageing and diseases came from studies of
identical twins. Human monozygous (“Identical”) twins
account for 1/250 live births. They arise from the same
zygote and therefore have the same DNA. However, in many
characteristics, there is a relatively high rate of discordance.
That is, there are numerous instances where identical twins
develop different diseases. These include some conditions
that are seen early such as juvenile diabetes and autism, as
well as those conditions that are seen later in life, such as
ulcerative colitis and various cancers. There is no correlation
between the age of onset and the concordance between twins
(Petronis 2006).
The cause of this high discordance is not known, but recent
evidence suggests that differences in DNA methylation may
be involved. One possibility is that DNA methylation
patterns can differ between twins, even though their DNA is
identical. If a gene becomes methylated when it should not
be, it will be turned off, just as if the DNA had been mutated.
One loses function either way, and methylation is a much
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easier way to lose function. Similarly, anomalies arise if a
gene becomes unmethylated and then becomes active in the
wrong cells.
This appears to be the case for a pair of identical twin
girls, where one twin had a severe anomy—a duplicated
portion of the spine in the posterior portion of her body. Her
phenotype reminded clinicians of a similar phenotype in
mice, wherein the Axin1 gene has been mutated. Axin is an
inhibitor of the Wnt pathway in development, and in mice,
mutations of the Axin1 gene cause duplications of the caudal
axis—extra spines (and bifurcated tails). Moreover, in mice,
methylation of the Axin1 promoter will repress the gene and
prevent its from functioning, also giving an abnormal tail
phenotype. Blood samples showed that although both twin
girls had the same allele for AXIN1, there was signiﬁcantly
more methylation at this locus in the affected twin than in
the unaffected twin or in the twins’ parents (Oates et al.
2006). The regions around this gene showed no signiﬁcant
differences in methylation.
Most “identical” twins, however, start off life with very
few differences in appearance or behaviours, but accumulate
these differences with age. Experience counts, and both
random events and lifestyles may be reﬂected in phenotypes.
Mario Fraga and colleagues in Manel Estelle’s laboratory in
Madrid found that twin pairs were nearly indistinguishable
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in methylation patterns when young, but older monozygous
twins exhibited very different patterns of methylation.
This affected their gene expression patterns, such that
older twin had different patterns of DNA expression, while
younger twin pairs had very similar expression patterns.
Monozygotic twin pairs start off with identical amounts
of methylated DNA, Histone H4 acetylation, and Histone
H3 acetylation (three epigenetic markers). However as the
twins get older, methylation increases in both twins, but
to different extents. Similarly, acetylation differences also
increase.
Not only does the amount of methylation change as twins
age, but so does the pattern of methylation. This can be
shown by looking at speciﬁc genetic sequences where one
cuts with enzymes that are sensitive to methyl groups on the
cytosines. Thus, there are some enzymes that will cleave
DNA at a sequence containing a C residue, but will not
cut that sequence if the C is methylated. As twins age, the
there is an increase in the discrepancies between the twin’s
DNA. Therefore, methylation differences may be critical in
causing twins to phenotypically diverge as they grow older
and to be discordant for different diseases, as well.
The idea that random epigenetic drift inactivates important
genes without any particular environmental cue gives rise to
an entirely new hypothesis of ageing. Instead of randomly
accumulated mutations – which might be due to speciﬁc
mutagens – we are at the mercy of chance accumulations
of errors made by the DNA methylating and demethylating
enzymes. Indeed, our DNA methylating enzymes,
unlike the DNA polymerases, are prone to errors. DNA
methyltransferases are not the most fastidious of enzymes.
At each round of DNA replication, they must methylate the
appropriate Cs and leave the other Cs unmethylated, and this
is not always done properly.
This hypothesis of random epigenetic drift may have
profound affects on physiology. For instance, the methylation
of the promoter region of the estrogen receptors are known
to increase with age (Issa et al. 1994). There is a linear
relationship between the methylation of a promoter region in
estrogen receptor gene with increased age. The methylation
of the promoters of the genes for the alpha and beta estrogen
receptors increases with age, resulting in the inactivation of
this gene activation in the smooth muscles of the circulatory
system. Moreover, methylation of the estrogen receptor
genes is even more prominent in the atherosclerotic plaques
that occlude the blood vessels. The atherosclerotic plaques
showed more methylation of the estrogen receptor genes
than did the tissue around it (Post et al. 1999; Kim et al.
2007) Thus, DNA methylation associated inactivation of the
estrogen receptor genes in vascular tissue may play a role
in atherogenesis and ageing of the vascular system. This
potentially reversible defect may provide a new target for
intervention in heart disease.
J. Biosci. 34(4), October 2009

So we now have a new hypothesis for ageing. There
appears to be random epigenetic drift that is not determined
by the type of allele or any speciﬁc environmental factor.
Random epigenetic drift may cause the ageing phenotype
as different genes randomly get repressed or ectopically
activated. Mistakes in the DNA methylation process
accumulate with age, and may be responsible for the
deterioration of our physiology and anatomy. If this is
so, some genes may be more important than others. The
estrogen receptors, for instance, are critical in vascular,
skeletal, and muscular health.
2.

Cancer

But there are some genes that are even more important to
be properly regulated. These are the genes that prevent
cancers. There are two types of genes involved in cancer
production. The ﬁrst are oncogenes. These are the genes that
promote tumour formation and metastasis (spread of cancer
cells throughout the body). They are the genes that promote
cell division, reduce cell adhesion, and prevent cell death.
The second set of genes are the tumour suppressor genes.
These genes usually put breaks on cell division and increase
the adhesion between cells. These genes also can cause
apoptosis (cell death) of rapidly dividing cells.
These oncogenes and tumour suppressor genes have to
be very ﬁnely regulated. In the stem cells of the skin, gut,
and blood, for instance, there has to be a very carefully
controlled rate of cell division. In the epithelial cells that
make up your kidney and lungs, cell division is much rarer.
Thus, one might get cancers if faulty methylation either
inappropriately methylated the tumour suppressor genes or
inappropriately demethylated the oncogenes.
In the breast, estrogen receptors can act as oncogenes
for estrogen-dependent breast cancer. Moreover, in breast
tissue, there is an age-related increase in the methylation
of the promoter of the RASSF1A gene, whose product is a
tumour suppressor. This methylation has been correlated
with the risk of breast cancer (Euhus et al. 2008). In the
colon, however, estrogen stops the proliferation of cells,
and the estrogen receptors function as tumour-suppressor
genes. Issa and colleagues (1994) showed that in addition
to the age-associated methylation of the estrogen receptors,
there was a much higher level of DNA methylation in the
estrogen receptor genes in colon cancers. Even the smallest
colon cancers had nearly 100% methylation of the estrogen
receptor promotor. Moreover, microarrays (which detect
differences in mRNA populations) identiﬁed numerous
genes whose methylation patterns changed dramatically in
colon cancer cells (Schuebel et al. 2007).
In addition to the age-related onset of tumours. DNA
methylation can also explain the etiology (cause) of several
lifestyle-related tumours. For instance, tobacco smoke is
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known to cause cancer, but it is not a very powerful mutagen.
Russo and colleagues (2005) and Liu and colleagues (2006)
found that lung cancers caused by cigarette smoke had
several tumour suppressor genes heavily methylated.
These included the genes encoding cell adhesion proteins,
apoptosis accelerators, and mitosis inhibitors. In addition,
Liu and colleagues (2007) showed that the synucleingamma gene, a gene that is not normally expressed in lung
tissues, is activated by cigarette smoke. This gene appears to
be demethylated, and its activation promotes the spread of
the tumour to other parts of the body.
The mechanism by which the synuclein-gamma gene is
demethylated gives us an important clue as to how tumours
can occur. The current model of tumour formation is a genecentered model wherein a particular cell accumulates over a
dozen new mutations. This seems probabilistically unlikely.
But in the cancer model presented here, DNA methylation,
not DNA mutation, causes the deﬁciency of proteins. The
cause for the demethylation of synuclei-gamma appears
to be the downregulation of a gene that encodes the
methyltransferase enzyme DNMT3B, which usually adds
methyl groups to DNA.
3. The reciprocity of epigenetic and genetic causation
in cancer
The epigenetic causation of cancer does not exclude a
genetic cause. Indeed, several studies indicate that these
mechanisms augment one another. Numerous mutations
occur in each cancer cell, and recent evidence suggests that
as many as fourteen signiﬁcant tumour-promoting mutations
are found in each cancer cell (Sjöblom et al. 2006). Feinberg
and colleagues (2006) have proposed that the ﬁrst stage of
tumour development is an epigenetic alteration of the DNA
in a progenitor cell such that it will enable mutations to
accumulate in other portions of the genome, and Jacinco
and Esteller (2007) have shown that the large number of
mutations that accumulate in cancer cells has an epigenetic
cause. DNA has several means of protecting itself from
mutations. One is the editing subunits on DNA polymerase
which get rid of mismatched bases and insert the correct
ones. Another mechanism is the set of DNA repair enzymes.
These enzymes repair DNA that has been damaged by light
or by cellular compounds that are products of metabolism. In
cancer cells, the genes encoding these DNA repair enzymes
appear to be susceptible to inactivation by methylation.
Once these DNA repair enzymes have been downregulated,
the number of mutations increases. Therefore, ageing and
cancer may be linked in having the common denominator of
aberrant DNA methylation. If metabolically or structurally
important genes (such as the estrogen receptors) become
heavily methylated, they do not produce enough receptor
proteins, and our body functions more poorly. If tumour
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suppressor genes or the genes encoding DNA repair enzymes
are heavily methylated, tumours can arise.
In this model of cancer development, genetic changes
are not nearly as critical as the epigenetic changes. This
provides an organizational framework for a great deal of data
that have accumulated indicating that many cancers have
normal genomes (reviewed in Sonnenschein and Soto 1999;
Gilbert, 2006). Some cancer cells can actually revert back to
being normal cells when put into appropriate environments
or when given chemicals that cause them to differentiate
(Stewart and Mintz 1981; Altucci and Gronemeyer 2001;
Bissell et al. 2002). So these cancer cells have been thought
to be epigenetically rather than genetically altered.
However, even as one ﬁnds that epigenetic mechanisms
may cause mutations, one also ﬁnds that mutations can be the
cause of epigenetic silencing. For instance, as many as 5%
of all the genes in tumour cells might be hypermethylated
(Schuebel et al. 2007). One of the most important oncogenes
is the Ras small G-protein. This oncogene is known for its
ability to initaiate signalling transduction cascades that
phosphorylate certain transcription factors that promote
tumourigenesis. However, Ras can also act by a second,
epigenetic, cascade (Gazin et al. 2007). Through a pathway
composed of at least 28 proteins (including the DNMT1
methyltransferase), activated RAS is able to silence the
Fas gene that enables the rapidly dividing cells to commit
apoptosis. The active Ras protein thereby recruits DNMT1
to the promoter of the fas gene, where it hypermethylates the
promoter and stops its tumour-suppressor function.
Tumours can be generated by a combination of genetic
and epigenetic means. Changes in DNA methylation can
activate oncogenes and repress tumour-suppressor genes,
thereby initiating tumour formation. Conversely, oncogenes
can cause the methylation of tumour suppressor genes,
which also aids in tumourigenesis. Moreover, the tissue
environment of the cell may be critical in regulating
these processes. This may be especially true in the stem
cell niche, where ageing might allow the selection of
oncogenic mutations (see Marusyk and DeGregori 2008).
The complexities of tumours, including their multiple
somatic mutations and there resistance to agents that induce
apoptotic cell death, may best be explained by a combination
of genetic and epigenetic factors more than just on the basis
of mutations. Moreover, knowledge of the epigenetic causes
of cancer can provide the basis for new methods of cancer
therapy.
4.

Conclusion

Ageing and cancer have epigenetic components wherein
genes can be inappropriately activated or repressed by
demethylation and methylation. Physiologically important
genes, when repressed, can lead to the changes seen in ageing,
J. Biosci. 34(4), October 2009
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and areas of marked suppression have been associated with
atherosclerotic plaques and other phenomena characteristic
of the ageing syndrome. When epigenetic processes activate
oncogenes or inactivate tumour suppressor genes, cancer
can arise. The large number of mutations in tumour cells
might emerge from previous epigenetic events that prevent
DNA repair functions from taking place. These new insights
can lead us to better preventive measures in public health
and better treatments through drug design.
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